Oncology & Hematology FI

Danish Evening at EHA 2024 was an evening filled with inspiring presentations, discussions, social interaction, and networking among the participants. If you did not participate in Danish Evening, you can read the highlights from the presentations in this article. #EHA24 #Hematology

In this MEDtalk, Fredrik Schjesvold explains that there is still an unmet need for treatment for patients with multiple myeloma. One of the new options is treatment with selinexor, which Fredrik Schjesvold puts into perspective in relation to mode of action, effect, side effects, and placement in clinical treatment #Myelomatose #Treatments #ClinicalKnowledge

New evidence suggests no benefit in adding immune checkpoint inhibitors to cabozantinib for patients with metastatic renal cell carcinoma who have progressed after prior immune checkpoint inhibitors therapy. #KidneyCancer #RenalCellCarcinoma

The combination of enzalutamide and Ra-223 as first-line therapy for patients with bone metastatic castration-resistant prostate cancer significantly improves rPFS. This improvement was supported by a significantly improved OS and also by a statistically significant improvement in time to next systemic treatment, Silke Gillessen concludes in this MEDtalk from the ESMO - European Society for Medical Oncology 2024 Congress in Barcelona. 🔗See more from ESMO24: https://lnkd.in/dW66xcnP #ESMO24 #Prostatecancer

The iStopMM study provides valuable new data on precursors of multiple myeloma, proposing a novel definition for light chain smoldering myeloma and identifying key risk factors for MCAS. #Myeloma #Treatments #Knowledgesharing

Professor Tony Mok, Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong, presents two outstanding lung cancer results from ASCO 2024 in this MEDtalk. He also gives his perspective on a new KRAS-G12C inhibitor based on the CRYSTAL-12 trial. 🔗 Read more about ASCO 2024 here: https://lnkd.in/d3_X3GTg #ASCO24 #LungCancer #Treatment

At this year’s ESMO congress, the long-awaited final overall survival in patients with newly diagnosed advanced ovarian cancer treated with the parp-inhibitor niraparib as first-line maintenance therapy was presented. In this MEDtalk, Mansoor Raza Mirza from Rigshospitalet in Denmark, presented the results of the PRIMA trial. He also perspectives the status of treatment of ovarian cancer with immunotherapy. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dW66xcnP #ESMO24 #OvarianCancer #Immunotherapy

Hear Andrea Botticelli present the primary results of the ROME trial in this MEDtalk from ESMO 2024. The study demonstrated that a mutational-based treatment approach based on the Molecular Tumor Board discussion of comprehensive genome profiling results may significantly improve ORR and PFS compared to standard of care in pretreated patients with metastatic solid tumors, particularly with immunotherapy. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dW66xcnP #ESMO24 #Immunotherapy #Tumor

Marco Donia moderated a press conference on immunotherapy at the 2024 ESMO - European Society for Medical Oncology congress . In this MEDtalk, he discusses significant updates on neoadjuvant treatments for stage 3 melanoma, where immunotherapy before surgery improves outcomes, mainly when a significant pathological response is achieved. 🔗See more from ESMO24: https://lnkd.in/dW66xcnP #ESMO24 #Immunotherapy #Melanoma

Astrid Lahousse presents: This article explores the effect of psychologically informed practice with behavioral graded activity in cancer survivors. #Cancer #Therapy #QualityOfLife